HighField Biopharmaceuticals Announces First Patient Dosed in Phase 1b/2 Trial of HF1K16 for Recurrent and Refractory Glioma
HF1K16 is a new immuno-oncology drug targeting myeloid-derived suppressor cells (MDSC) to treat cancerHANGZHOU, CHINA--HighField Biopharmaceuticals (HighField Bio), a clinical stage immuno-oncology co ...